Follow The Filings

PALI Palisade Bio

Palisade Bio earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 9 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by PALI's executives, directors and 10% owners in the last 12 months, from their Form 4s

All PALI insider trades
  • $297K bought by 2 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Donald Allen Williams Director
    Buy
    $29K 20,000 shares at $1.44 +1.3% to stake
    Traded Oct 1–2 Filed Oct 5
  2. Robert Baltera Jr. Director
    Buy
    $89K 45,000 shares at $1.97 +11% to stake
    Traded Jul 8–9 Filed Jul 10
  3. Robert Baltera Jr. Director
    Buy
    $102K 50,000 shares at $2.04 +14% to stake
    Traded Jul 6–7 Filed Jul 8
  4. Robert Baltera Jr. Director
    Buy
    $59K 30,000 shares at $1.98 +8.9% to stake
    Traded Jul 1–2 Filed Jul 6
  5. Donald Allen Williams Director
    Buy
    $8,356 5,000 shares at $1.67 +87% to stake
    Traded Jan 16 Filed Jan 21
  6. Donald Allen Williams Director
    Buy
    $9,400 5,000 shares at $1.88 +687% to stake
    Traded Jan 9 Filed Jan 13

Also filed in the last 12 months, not counted as buying or selling: 10 option exercises, 6 stock grants, 4 sales to cover taxes, 2 share withholdings for taxes, and 2 gifts.

SEC filings

Recent issuer filings from EDGAR, 23 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
SCHEDULE 13G —
8-K 5.02,5.03,5.07,9.01
SCHEDULE 13G —
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
DEF 14A
DEFA14A
8-K 8.01
10-K
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.